Compare ZWS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZWS | PRAX |
|---|---|---|
| Founded | 1900 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 9.0B |
| IPO Year | 2008 | 2020 |
| Metric | ZWS | PRAX |
|---|---|---|
| Price | $50.43 | $337.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $53.67 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.1M | 326.2K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,530,500,000.00 | N/A |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $5.13 | $7,758.26 |
| P/E Ratio | $146.34 | ★ N/A |
| Revenue Growth | ★ 19.40 | N/A |
| 52 Week Low | $33.95 | $34.89 |
| 52 Week High | $53.76 | $354.87 |
| Indicator | ZWS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 55.91 |
| Support Level | $44.89 | $282.49 |
| Resistance Level | $51.18 | $353.83 |
| Average True Range (ATR) | 1.60 | 18.75 |
| MACD | 0.09 | -0.96 |
| Stochastic Oscillator | 54.39 | 69.67 |
Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.